// App-Quantinova.ai

8 : Long-Term Efficacy and Safety Data for Dupilumab in a Phase 3, Open-Label Extension Trial (LIBERTY AD PED-OLE) in Patients Aged â?¥6 to <12 Years With Uncontrolled, Moderate-to-Severe Atopic Dermatitis (AD)

Researchers

Presenter

  • Dimittri Delevry

Principal Investigators

  • Diamant Thaçi

  • Lawrence Eichenfield

  • Peter D. Arkwright

  • Zhen Chen

  • John T. O'Malley

  • Ashish Bansal

Medical Centers

  • University of Manchester, Manchester, United Kingdom

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.

  • University of Sheffield, Sheffield, United Kingdom

  • Universitat zu Lubeck Lübeck Germany

  • None Cambridge Massachusetts United States

Locations

  • United States

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

Disease

  • Atopic Dermatitis

Biomarkers

  • N/A

Drug/Treatment

  • Dupilumab

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • III

Study Id's

  • NCT02612454

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved